Drugs / Ocular Surface Immune Globulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04510428 | May → Nov 2023 | dry eye syndrome | University of Illinois at Chicago | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ocular Surface Immune Globulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04510428 ↗ |
| Known as | OSIG | “Ocular Surface Immune Globulin (OSIG) eye drops 4 mg/ml (0.4%) four times a day for 8 weeks” NCT04510428 ↗ |
| Route | Topical | “OSIG) eye drops” NCT04510428 ↗ |